TRCT
CDLX icon

Tower Research Capital (TRC)’s Cardlytics CDLX Stock Holding History

Tower Research Capital (TRC)’s Portfolio CDLX Stock Details CDLX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$3.02K Buy
+673
New +$5.03K ﹤0.01% 4587
2025
Q4 		– Sell
-561
Closed -$13.6K – 5193
2025
Q3 		$13.6K Sell
561
-96
-15% -$1.6K ﹤0.01% 3666
2025
Q2 		$10.8K Buy
657
+170
+35% +$2.94K ﹤0.01% 3935
2025
Q1 		$8.77K Buy
487
+178
+58% +$5.08K ﹤0.01% 3853
2024
Q4 		$11.5K Sell
309
-817
-73% -$31.3K ﹤0.01% 3712
2024
Q3 		$36K Buy
1,126
+647
+135% +$35.9K ﹤0.01% 2908
2024
Q2 		$39.4K Buy
479
+79
+20% +$8.54K ﹤0.01% 3280
2024
Q1 		$57.9K Sell
400
-560
-58% -$47.3K ﹤0.01% 2172
2023
Q4 		$88.4K Buy
960
+746
+349% +$75.8K ﹤0.01% 2735
2023
Q3 		$35.3K Buy
214
+139
+185% +$18.1K ﹤0.01% 2873
2023
Q2 		$4.71K Sell
75
-2,549
-97% -$154K ﹤0.01% 4910
2023
Q1 		$89K Buy
2,624
+1,265
+93% +$66.1K ﹤0.01% 1972
2022
Q4 		$79K Buy
1,359
+1,018
+299% +$62.9K ﹤0.01% 2012
2022
Q3 		$32K Buy
341
+235
+222% +$33.4K ﹤0.01% 3539
2022
Q2 		$24K Buy
106
+21
+25% +$7.03K ﹤0.01% 3592
2022
Q1 		$46K Buy
85
+1
+1% +$604 ﹤0.01% 2796
2021
Q4 		$56K Sell
84
-1
-1% -$764 ﹤0.01% 2673
2021
Q3 		$71K Sell
85
-3
-3% -$3.04K ﹤0.01% 2675
2021
Q2 		$111K Sell
88
-165
-65% -$186K ﹤0.01% 2338
2021
Q1 		$278K Buy
253
+66
+35% +$87.1K ﹤0.01% 1733
2020
Q4 		$268K Sell
187
-2,105
-92% -$2.25M 0.01% 1478
2020
Q3 		$1.62M Buy
2,292
+1,991
+661% +$1.45M 0.02% 544
2020
Q2 		$211K Buy
+301
New +$174K 0.01% 1744
2019
Q4 		– Sell
-408
Closed -$137K – 3600
2019
Q3 		$137K Buy
408
+106
+35% +$34K 0.01% 1179
2019
Q2 		$79K Sell
302
-53
-15% -$10.6K 0.01% 1295
2019
Q1 		$59K Buy
355
+163
+85% +$26.5K ﹤0.01% 1686
2018
Q4 		$20K Buy
+192
New +$32.4K ﹤0.01% 1928
2018
Q2 		– Sell
-27
Closed -$4K – 3671
2018
Q1 		$4K Buy
+27
New +$4.57K ﹤0.01% 2776

Other funds holding CDLX

CIP
CAS Investment Partners Westport, Connecticut $1.88B AUM 2.5% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
6CM
683 Capital Management New York $2.04B AUM 94.26% 1-Year Est. Return
KGAMU
KPS Global Asset Management (UK) London, United Kingdom $620M AUM 14.15% 1-Year Est. Return
WPM
Worldly Partners Management Needham, Massachusetts $122M AUM 11.49% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RC
RBF Capital San Francisco, California $2.41B AUM 39.41% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
QOP
Quinn Opportunity Partners Charlottesville, Virginia $2.16B AUM 28.56% 1-Year Est. Return
Jane Street
Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return

Tower Research Capital (TRC)'s CDLX Position: Q2 2026 in Review

Tower Research Capital (TRC) opened a new position in Cardlytics (CDLX) in Q2 2026: 673 shares worth $3.02K. The stake represents ﹤0.01% of the portfolio and ranks #4587 among its holdings. This is a return to the name: Tower Research Capital (TRC) previously reported a position in CDLX as recently as Q3 2025.

Tower Research Capital (TRC) first reported a position in CDLX in Q1 2018 and has held it in 28 quarters since. The position peaked at $1.62M in Q3 2020. 42 funds tracked by Wall St. Rank hold CDLX as of Q2 2026.

  • Tower Research Capital (TRC) held 673 shares of Cardlytics worth $3.02K as of Q2 2026.
  • Cardlytics was a new Tower Research Capital (TRC) position in Q2 2026.
  • Cardlytics made up ﹤0.01% of Tower Research Capital (TRC)'s portfolio in Q2 2026, its #4587 holding.
  • Tower Research Capital (TRC) first reported a position in Cardlytics in Q1 2018 and has held it in 28 quarters since.
  • Tower Research Capital (TRC)'s Cardlytics position peaked at $1.62M in Q3 2020.
  • 42 funds tracked by Wall St. Rank held Cardlytics as of Q2 2026.

Based on Tower Research Capital (TRC)'s 13F filing for Q2 2026, filed 11 Aug 2026.